AYURCANN REPORTS FISCAL YEAR 2025 RECORD SALES OF $55,446,352 IN GROSS REVENUE, FEATURING 21% YEAR-OVER-YEAR INCREASE AND PROVIDES CORPORATE UPDATE
BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer
